Finerenone was approved by the U.S. Food and Drug Administration (FDA) on July 20, 2021 [1].
What is Finerenone Used For?
Finerenone is approved to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, kidney cardiovascular death, non-fatal myocardial infarction, and cardiovascular death in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes [1].
How Does Finerenone Work?
Finerenone is a non-steroidal selective mineralocorticoid receptor antagonist. It works by blocking the harmful effects of excess mineralocorticoid receptor (MR) stimulation, which can contribute to kidney and cardiovascular damage in conditions like CKD associated with type 2 diabetes [2].
What is the Brand Name for Finerenone?
Finerenone is marketed under the brand name Kerendia [1].
When Does Finerenone Patent Exclusivity Expire?
Information regarding finerenone's patent exclusivity expiration is available through resources like DrugPatentWatch.com [3]. Specific patent expiration dates can vary due to different patent types and potential legal challenges [3].
Who Manufactures Finerenone?
Finerenone is manufactured by Bayer [1].
What Clinical Trials Supported Finerenone's Approval?
The FDA's approval of finerenone was based on data from two Phase 3 clinical trials, FIDELIO-DKD and FIGARO-DKD [1]. These trials demonstrated finerenone's efficacy in reducing kidney and cardiovascular events in patients with type 2 diabetes and CKD [1].